Founded in 2003 from the Department of Electronic and Electrical Engineering in collaboration with the University of Cambridge, Zinwave aims to provide sub-systems and systems for distributing wireless signals, including those for applications such as cellular radio and WLAN in a flexible, future proof and low cost manner. Zinwave’s proprietary technology enables these applications to be serviced using low cost multi-mode fibres, giving rise to significant cost savings for system providers and installers.
Yaqrit Limited is a UK-based company specialising in interventions in liver disease based on 20 years of research and development at UCL.www.yaqrit.com
ThioLogics is a UCL spin-out company developing a technology platform that will enable the homogeneous modification of native polypeptides. Specifically, we have discovered groundbreaking technology, based on Next Generation Maleimides, that allows the selective bridging and functionalisation of disulfide bonds in antibodies, proteins and peptides. We are particularly focused on the application of our technology to the assembly of homogeneous antibody conjugates.
Technology that will allow modification of antibodies to yield homogeneous products is highly desirable. In particular, it has been demonstrated that homogeneous antibody drug conjugates (ADCs) have a greatly improved therapeutic index over analogous heterogeneous formulations. Introducing greater homogeneity into antibody conjugates will also greatly simplify process and development issues, thereby reducing costs.
For further information, please visit www.thiologics.com
Synthace is the UK’s first dedicated synthetic biology company with a world-leading platform of technologies for the rapid engineering and optimisation of novel biological production systems.
Synthace is already producing high-value research and development products for the pharmaceutical, agrochemical and fine chemicals industry. Synthace bioengineering is enabled by a tight integration of computational modelling and big data analysis with wet lab experimental design and validation, and novel molecular biology tools. While Synthace bioengineering is broadly applicable across multiple industry sectors, the company is focused towards applications in the production of specialty chemicals.
More information is available at www.synthace.comwww.synthace.com
A London based biotech company pioneering the discovery and development of a unique class of low molecular weight sequence-specific DNA-interactive drugs designed to treat gene-mediated diseases. The company is commercialising a platform technology capable of discovering lead compounds that target any gene sequence. The therapeutic potential is in a broad range of diseases and physiological processes.
Founded in 1990 from UCL’s Bartlett School of Architecture, Space Syntax Limited offers a specialist consulting service in the design and evaluation of urban areas and building interiors, based on the principle that movement and communication are essential to the social and economic success of public and private space. This evidence-based approach to property and design consulting provides clients with clear advice and creative solutions.
Senceive Ltd was spun out from the Department of Electronic and Electrical Engineering to commercialise an innovative approach to the problem of monitoring distributed industrial environments such as railway infrastructures and underground mines. By utilising a number of small, intelligent devices that communicate through meshed radio networks, the company offers an autonomous solution that is easy for non-experts to install, maintain and use.
Satalia (NPComplete Ltd) provides ‘Optimisation-as-a-Service’ to academia and industry and is a spin-out from UCL.
Satalia SolveEngine was developed as a one-stop-shop for state-of-the-art optimisation algorithms giving industry immediate access to cutting edge technology that enables more intelligent use of compute resources and produces smarter, faster solutions to complex problems.
Satalia provides new economic models to allow academics to commercialise their algorithmic innovations and get access to critical data to improve their research, and gives producers of software tools a new revenue mechanism to support the development and exposure of their software.
This software platform includes five main components 1) a portal and API to allow the submission of optimisation problems and retrieve the solutions, 2) new optimisation translators and encodings to provide interoperability between algorithmic formats (such as SAT, CSP, FZN, LP, GPL, SMT, OPB, etc), 3) machine learning to intelligently match the right algorithms to the problems it receives, 4) distributed computation, running on public or private clouds and HPC, and 5) a management console to allow academics to include their algorithms on the platform, commercialise their IP and gain access to valuable data to enable better research.
The ‘Optimisation-as-a-Service’ platform is a conduit for academic algorithms into industry, and has wide reaching commercial applications across multiple sectors, including Finance, Bioinformatics, Logistics, Telecoms and Defence. Optimisation problems exist across the entire spectrum of computer science and engineering, and Satalia’s SolveEngine has already been used to solve hard computational problems in graph theory, logistics, system verification, BigData and cryptography.
To find out more about the SolveEngine visit www.satalia.netwww.satalia.com
PolyMASC’s patented pegylation and liposomes technologies helped them to be the first university spin out company to float on the London Alternative Investment Market in 1995. The company merged with Valentis Inc. in 2000. In July 2007, Urigen Pharmaceuticals Inc completed a reverse merger with Valentis Inc, Urigen Pharmaceuticals is a speciality pharmaceutical company dedicated to the development and commercialisation of therapeutic products for urological disorders.
Pentraxin Therapeutics Ltd is a UCL spin out company formed in 2001. It holds all the intellectual property and proprietary knowledge emanating from Professor Mark Pepys’ research at UCL. Pentraxin Therapeutics Ltd is concerned with the research and development of drugs for the treatment of amyloidosis and amyloid-related diseases such as Alzheimer’s disease and type II diabetes, as well as targeting the pathogenic effects of C-reactive protein in cardiovascular disease and inflammatory diseases.pentraxin.wordpress.com/
The first automatic futures and options exchange for digital media, MediaGamma is transforming the way digital media is valued, traded, and measured. The company which is spun out of the Department of Computer Science at UCL and is supported by UCL Business PLC (UCLB) was established in 2014 at the intersection of London’s tech, advertising, and finance hubs, MediaGamma’s customers include some of the UK’s leading brands, agencies, and publishers.
MediaGamma provides its partners with greater transparency and control when they buy and sell digital media by offering an accurate, ROI-based view of the immediate and long-term value of inventory. Brands, agencies, and publishers can also engage in programmatic direct or upfront inventory purchases and sales on the MediaGamma platform, mitigating price volatility and ensuring brand safety.www.mediagamma.com
Founded by Professor Derek Hill and Professor David Hawkes from the Centre for Medical Image Computing in conjunction with colleagues at Imperial College, Ixico provides image analysis services to the pharmaceutical industry. By coupling image analysis technology with expertise in image acquisition, the company is able to provide automated, scalable and authoritative information extraction solutions. Ixico will improve the quality and effectiveness of therapeutic interventions, both under development and in clinical use, through an automated service to extract relevant clinical information from images.
Helicon Health is committed to facilitating shared care for the management of long-term conditions. The company’s aim is to ensure that, as there is an increase in the number of patients managed outside the hospital environment, they also enhance the quality of care.
The Helicon Health goal is to help commissioners move towards a distributed service where the complex patients (10 – 15%) are managed in the hospital setting whilst the rest are either self-testing and self-managing, or being managed by the GP, an outreach service or their community pharmacy.
For more information visit www.heliconhealth.co.uk
EVEXAR Medical Ltd is a medical device company formed at one of the leading UK universities, University College London. EVEXAR was established in 2006 to address the need for disposable instruments designed and developed to address specific needs rather simply produce another ‘me too’ device adapted from its original use. Our emphasis is the design, development, manufacture and distribution of premium, single use, self-illuminated medical devices. Our product range:
SPECULUX is a range of single use, fully disposable and self-illuminating Vaginal Specula for use in examination, diagnosis and treatment in associated feminine healthcare. SPECULUX is available with or without a smoke tube which extracts smoke and aerosols produced when using diathermy. In both cases, SPECULUX is supplied in three sizes; small, medium and large with a choice of two closure systems, a screw thread or ratchet mechanism.
SIGMOLUX is a self-contained, single use, fully disposable, cable-less and self-illuminating Rigid Sigmoidoscope system designed to optimise mobility during diagnosis and treatment. SIGMOLUX is supplied fully assembled and complete with insufflator for inflating the bowel with a lens to provide a clear view of the observation area. SIGMOLUX uses our unique patented ‘CLEAR VIEW System’ which protects the light guide to give a clear and unobstructed view of the examination area.
PROCTOLUX is self-contained, single use, fully disposable, cable-less and self-illuminating and is available in 19mm and 25mm sizes. PROCTOLUX uses the our unique patented ‘CLEAR VIEW System’ which protects the light guide to give a clear and unobstructed view of the examination area.
All EVEXAR products are designed and manufactured to meet the requirements of the Medical Device Directive and bear the ‘CE’ mark
View the company in detail: www.evexar.comwww.evexar.com
EuroTempest Ltd is a venture established by Benfield, Royal & SunAlliance and UCL Business in the area of quantitative weather risk services. The company’s web-based service is recognised as providing the most advanced real-time 5 day forecasts of weather risk across Europe. EuroTempest’s services are targeted at companies who may have financial exposure due to extreme and un-seasonal weather such as the insurance and re-insurance industry.
Endomagnetics Ltd is a medical device company arising from the London Centre for Nanotechnology at UCL and the University of Houston. The company’s first product (SentimagTM) offers a highly sensitive hand-held magnetic sensing device which can accurately detect low concentrations of clinically introduced nanoparticles. The initial application for the device will be as an intra-operative medical device for sentinel node detection in breast cancer. Other potential applications are in cardiovascular disease, melanoma detection and in the non-destructive testing of materials.
Domainex was established by scientists from the Institute of Cancer Research, University College London and Birkbeck College, with seed funding from the Bloomsbury BioSeed Fund. The company works on cutting edge science to create fragments of protein molecules encoded by cancer causing genes, or those involved in viral infections which can then be targeted for drug development. The technology developed by Domainex will greatly assist the study of the 3D structures of protein molecules involved in cancer and viral infection. This will provide a greater understanding as to how these proteins work and lead to the identification of new therapeutic drugs.
Developed by Animal Systems, a spinout of UCL Business, Chirp is an innovative technology for one-click sharing of data using short clips of audio that sound like digital birdsong. Available as a free app for iPhone/ iPad and Android devices, it currently allows users of such devices to receive photos, contact details, web links from any device that can make a sound including ‘dumb’ objects such as doorbells and greeting cards. Chirp has interesting use cases in marketing, user authentication, and even second screening, as chirps work effectively over broadcast TV, radio and YouTube.chirp.io/
Founded in 2005, Canbex is a developer of active compounds in the field of spasticity and pain. The company develops peripherally-acting cannabinoid antagonists for the treatment of multiple sclerosis (MS) and other neurodegenerative diseases. Canbex Therapeutics is a joint investment collaboration with BBSF (Bloomsbury Bio-Seed Fund) and the recipient of a Wellcome translation award. The company portfolio includes two different series of compounds that have been extensively characterised in MS models. The company is a licensing vehicle for this breakthrough technology and research work is being carried on this project at UCL, Queen Mary’s and Cambridge Universities. The company is managed and supported by UCL Business’ management team.www.canbex.co.uk/
Formed in 1999, Biovex is a private biotech company, based near Oxford, developing a new class of potent vaccines to treat and prevent cancer and certain viral diseases. The company has two vaccine platforms; OncoVEX and ImmunoVEX, and a functional genomics platform for gene target validation in neurons and other tissues (NeuroVEX). The Company`s lead product has completed Phase I clinical trials with Phase II studies in melanoma, breast cancer and head and neck cancer begun in October 2006. UCLB are delighted to announce that US biotechnology giant Amgen acquired Biovex in February 2011.
Autolus is a private biopharmaceutical company, focused on the development and commercialisation of engineered T-cell immunotherapy products with extreme efficacy in treatment of life-threatening cancers. Using its proprietary platform, Autolus is developing next-generation engineered CAR T-cell products, and is positioned to be a leader in the use of human cells to treat disease. It is expected that this platform will provide a source of sustainable competitive advantage in both haematological and solid cancers, most of which are not addressable using the current CAR technology. Autolus’ shareholders include Syncona LLP and UCL Business PLC. For further information please visit the Company’s website at: www.autolus.comwww.autolus.com
AtoCap Ltd is commercialising a novel electro-hydrodynamic processing technology that was developed within the Department of Mechanical Engineering and which enables the preparation of a wide range of encapsulated structures via a clean, efficient, one step route. Atocap’s platform technology developed by Prof. Mohan Edirisinghe and Prof. Eleanor Stride has potential applications spanning the pharmaceutical, chemical, cosmetic and food manufacturing sectors. The first application area for the company focuses on the encapsulation of antibiotics in a controlled release formulation to enable urinary tract infections to be treated in a targeted manner via a single minimally invasive injection.
Arrow Therapeutics is a London-based pharmaceutical company focussed exclusively on research and development of novel antiviral drugs. The company has developed a broad pipeline of early and late stage projects at various stages between early research and clinical development. Their in-house research has resulted in compounds active against Hepatitis C and Respiratory Syncytial Virus. The leading RSV compound is currently in a phase II clinical trial and was the cornerstone of a deal with Novartis to develop and commercialise the small molecule inhibitor RSV604 (previously known as A-60444) for the treatment of Respiratory Syncytial Virus. Further breakthroughs have lead to their acquisition by AstraZeneca, for circa $150m cash.
A European biotechnology company, Ark Therapeutics was established in July 1997 by Professor John Martin, Mr Stephen Barker and Professor Seppo Yla-Herttuala. Its Finnish arm, Ark Therapeutics Oy, was acquired in 2001. The company has a broad range of products in late stage clinical development. The therapeutic focus is on clear unmet clinical needs within the high value specialist medical areas of vascular disease and cancer. Ark successfully floated on the London Stock Exchange in March 2004.
Established in 1998, ADT is a joint venture company with Ebara Corporation of Japan to commercialise turbo-design software developed by Professor Mehrdad Zangeneh at UCL. The company has become a global leader, with clients representing some of the leading companies in the aerospace, automotive, power generation and marine fields.
Abzena provides a suite of complementary services and technologies to R&D organisations to improve the chances of successful development of therapeutic proteins and antibodies, and it is therefore poised to capitalise on the growth of the biopharmaceutical market. The Group has significant know-how, supported by a broad patent estate, to enable it to create better biopharmaceuticals for its customers.
Abzena operates a balanced business model with growing revenues from its service business and the potential for significant future growth through royalty bearing licences for the application of its technologies to biopharmaceutical products. The Group’s technologies and services are provided through its wholly-owned subsidiaries, PolyTherics and Antitope.
PolyTherics and Antitope have been developing and offering their technologies and services for over 10 years and their scientists have provided expertise to a wide range of companies, including most of the top 20 biopharmaceutical companies, many large and small public and private biotech, and academic groups, across the world.www.abzena.com/home
Abcodia Ltd is a biomarker company focussing on the validation of molecular biomarkers for disease diagnosis and personalised medicine. At the heart of the company is a unique biobank, the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) founded in 2001 and led by clinical scientists at UCL. UKCTOCS is the world’s largest prospective study for ovarian cancer diagnosis and will result in the generation of a collection of more than 5 million high quality serum aliquots (UKCTOCS sample bank), associated with clinical demographic and age-related disease phenotypic data from over 200,000 women across the UK. A wide range of diseases are now recorded across this aging cohort, making it amenable to the discovery of biomarkers and screening diagnostics for several therapeutic areas.